Temporal association of prostate cancer incidence with World Trade Center rescue/recovery work

David G Goldfarb,1,2 Rachel Zeig-Owens,1,2,3 Dana Kristjansson,4,5 Jiehui Li,6 Robert M Brackbill,6 Mark R Farfel,6 James E Cone,6 Janette Yung,6 Amy R Kahn,7 Baozhen Qiao,7 Maria J Schymura,7 Mayris P Webber,2,3,8 Christopher R Dasaro,9 Moshe Shapiro,9 Andrew C Todd,9 David J Prezant,1,2,3 Paolo Boffetta,10,11 Charles B Hall12

ABSTRACT

Background  The World Trade Center (WTC) attacks on 11 September 2001 created a hazardous environment with known and suspected carcinogens. Previous studies have identified an increased risk of prostate cancer in responder cohorts compared with the general male population.

Objectives  To estimate the length of time to prostate cancer among WTC rescue/recovery workers by determining specific time periods during which the risk was significantly elevated.

Methods  Person-time accruals began 6 months after enrolment into a WTC cohort and ended at death or 12/31/2015. Cancer data were obtained through linkages with 13 state cancer registries. New York State was the comparison population. We used Poisson regression to estimate hazard ratios and 95% CIs; change points in rate ratios were estimated using profile likelihood.

Results  The analytic cohort included 54,394 male rescue/recovery workers. We observed 1120 incident prostate cancer cases. During 2002–2006, no association with WTC exposure was detected. Beginning in 2007, a 24% increased risk (HR: 1.24, 95% CI 1.16 to 1.32) was observed among WTC rescue/recovery workers when compared with New York State. Comparing those who arrived earliest at the disaster site on the morning of 11 September 2001 or any time on 12 September 2001 to those who first arrived later, we observed a positive, monotonic, dose-response association in the early (2002–2006) and late (2007–2015) periods.

Conclusions  Risk of prostate cancer was significantly elevated beginning in 2007 in the WTC combined rescue/recovery cohort. While unique exposures at the disaster site might have contributed to the observed effect, screening practices including routine prostate specific antigen screening cannot be discounted.

INTRODUCTION

The period between potential exposure to carcinogens and the development of prostate cancer is of interest from both clinical and public health perspectives. The exact amount of time between an exposure and the development of cancer in an individual is dependent on many factors including the type and dose of exposure. While estimates vary considerably, for prostate cancer, studies have demonstrated it can take between 10 and 20 years following exposure for cancers to be diagnosed.1,2 These findings, however, are based on outdated reviews of evidence and do not account for advancements in screening.14 This is particularly challenging given the high sensitivity of prostate-specific antigen (PSA) testing, and prolonged lead time of disease which has resulted in early detection of presymptomatic individuals.3-7

Recent studies have identified an increased incidence of prostate cancer among World Trade Center (WTC)-exposed responders (rescue/recovery workers) when compared with the general male population.8-11 However, the length of time between exposure to the toxic environment at the disaster site beginning on 11 September 2001 (11 September) and onset of cancer remains unknown. Carcinogens known to be present in unknown. Carcinogens known to be present in the WTC environment include asbestos, benzene, chromium, dioxins and polychlorinated biphenyls (PCBs).4,5,12-14 These substances are classified by the International Agency for Research on Cancer as either probable or possible human carcinogens. The presence of these substances in the environment has been well described and is referenced in the large number of studies demonstrating an increased risk of cancer among WTC responders.4-6,8-11,13,17-19 However, the specific period during which the risk is elevated remains unknown.
polychlorinated biphenyls. Some have suggested that these contaminants may increase the likelihood of prostate cancer and expedite oncogenesis, however, this result was not found by all. Building on this hypothesis, one study which compared inflammatory gene expression among WTC and non-WTC-exposed prostate cancer patients found a higher differential expression of genes related to damage to DNA repair pathways and glycolysis among tissue samples of WTC-exposed patients. The study also found a Th17 inflammatory response in the prostate tissue of rats exposed to WTC dust.

The current prospective cohort study will expand on previous research revealing an increased incidence of prostate cancer among WTC-exposed workers by combining three WTC-exposed responder cohorts (the Fire Department of the City of New York (FDNY), the General Responder Cohort (GRC), and the World Trade Center Health Registry (WTCHR)) to provide the statistical power needed to explore the length of time to prostate cancer diagnosis using piecewise exponential change point models. This methodology has been previously used in studies of respiratory diseases in WTC-exposed subjects and in other research. The study aim was to determine the average time interval between 11 September exposure and observed increases in prostate cancer incidence, taking into account changes expected from ageing and secular trends in New York State (NYS). The amount of time from WTC exposure to the diagnosis of prostate cancer was estimated by determining the specific time periods between 2002 and 2015 during which the risk was significantly elevated compared with the NYS rate.

METHODS

Study population

The source population for this study included rescue/recovery workers (n=69,102) from three WTC-exposed responder cohorts: the FDNY, the GRC, and the WTCHR. Responders included firefighters, emergency medical service providers, police, construction and communication workers, volunteers and cleanup workers. While the WTCHR also includes persons who resided, went to school, or worked (in non-rescue/recovery positions) at the WTC disaster site, this study included only rescue/recovery workers. Additional details regarding consolidation of the WTC combined rescue/recovery cohort and data harmonisation have been described elsewhere. To avoid selection bias, persons who enrolled into any of the cohorts after October 1, 2012, when cancer coverage began under the James Zadroga 9/11 Health and Compensation Act, were excluded from all analyses. Under the provisions of this enactment, WTC Health Programme members have access to diagnostic procedures and treatment for numerous cancers and thus, to avoid differential self-selection into the cohort were removed. Figure 1A is a flow diagram of study participants for the WTC combined rescue recovery cohort (n=54,394), enumerating the exclusionary criteria.

Outcome assessment

Prostate cancer cases defined as ICD-O-3 site C619 with malignant behaviour code 3, using the Surveillance, Epidemiology and Cancer Surveillance (SECS), and the National Cancer Institute’s SEER*Stat (SEER) database and the specific time periods between 2002 and 2015 during which the risk was significantly elevated compared with the NYS rate.

Figure 1 Flow of study participants. FDNY, Fire department of the City of New York; GRC, General Responder Cohort; WTCHR, World Trade Centre Health Registry.
and End Results (SEER) site recode table, were obtained by matching the WTC combined rescue/recovery cohort to data from 13 state cancer registries. These states included Arizona, California, Connecticut, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Texas, Virginia, and Washington. We have examined out-migration patterns from New York City based on US Census Bureau American Community Survey data, a summary by the New York City Independent Budget Office, and our records for the rescue/recovery workers, and have concluded that the 13 registries! resulted in approximately 90% coverage of the population. Information on tumour characteristics such as diagnosis date and stage were also provided by state cancer registries. Cancer cases obtained from multiple states registries for the same participant were reconciled and included as one case. Cancer diagnoses within 6 months of enrolment into any of the responder cohorts were excluded from all analyses to ensure that prevalent cases were removed and to account for potential self-selection bias (i.e., selectively enrolling into a WTCHP cohort to receive augmented cancer coverage).

Exposure measures and demographic characteristics
Researchers from the three participating cohorts developed common exposure metrics to ensure that results from collaborative studies, such as this one, be comparable. The exposure measure for our primary external analysis was presence at the WTC site, or WTC rescue/recovery work at other sites such as the Fresh Kills Landfill in Staten Island, at any time from 11 September 2001 to 30 June 2002, the time when work on the recovery effort ended. We also used a three-level exposure variable according to self-reported first arrival at a WTC disaster site: on 11 September 2001 or being caught in the dust cloud resulting from the collapse of the towers on the morning of the attacks; or on 12 September 2001; or on any other time from 13 September 2001 to 30 June 2002. Some of the hazardous substances found to be present at the disaster site are known carcinogenic agents including, but not limited to, asbestos, sulfuric acid, benzo(a)pyrene, benzene, and arsenic, which we have posited were most ubiquitous on 11 September 2001, and gradually dissipated thereafter. Basic demographic characteristics such as sex, birth month, birth year, race/ethnicity, and smoking status were available in each cohort. Since only birth month and year were available for some study participants, the 15th of each month was used to calculate age. When both birth month and day were missing, 15 June of the birth year was used. Death dates were obtained by each cohort and duplicate patients as well as discordant dates of enrolment, diagnosis and death were resolved by the New York State Cancer Registry to ensure accurate ascertainment and person-time contributions. Death ascertainment by cancer registries is commensurate with completeness of mortality matches.

NYS comparison population
NYS population rates were used for the comparison population for our primary external analysis and were calculated using SEER*Stat software. Data were summarised in strata of person-time and cases by race/ethnicity (non-Hispanic White, non-Hispanic Black, non-Hispanic Asian/Pacific Islander, non-Hispanic American Indian and Hispanic), age (18–19, and 20 to 85+ in 5-year increments) and calendar year (2002–2015).

Statistical analyses
The outcome for all multivariable analyses was incident prostate cancer. Both comparison rates and observed cancer counts included multiple primary cancers. That is, every identified prostate cancer was counted as a case regardless of a patient’s cancer history (other than prostate). WTC combined rescue/recovery cohort data were grouped in strata of person-time and cases in the same way as the NYS comparison population. Person-time accruals began 6 months after enrolment into a WTC rescue/recovery cohort. This date was chosen so that prevalent cancers which had likely developed prior to 11 September 2001 were not misclassified as incident cases. The follow-up period ended at the earlier of date of death and 31 December 2015.

We used piecewise exponential survival models to estimate hazard ratios (HRs) and associated 95% CIs. These models are similar to Cox regression models, but they allow the baseline hazard to change at numerous specified time intervals rather than with every event; we used 1-year time intervals. The models also allow for incidence to be estimated in the reference group. The HRs also have rate ratio interpretations. These rate ratios were allowed to vary over follow-up using change points. Specifically, these change point analyses were conducted to estimate the yearly intervals for which relative incidences significantly changed from one period to the next.

We first fit a model with no change points which assumed constant incidence rates for both the WTC and NYS groups throughout the entire follow-up period. Then, we fit a series of models with one change point, allowing each model to change incidence rates at a different follow-up time, at yearly intervals, with change points varying from 2003 to 2014, resulting in a total of 12 possible models. The change points were estimated using profile likelihood and we reported estimates and 95% CIs for the HRs which have relative rate interpretation. Best fitting models were selected using likelihood ratio tests. The same process was used for models comparing two change points to one change point. In each case the combination of change points was run in separate models and then compared by profile likelihood. The specific model was

\[
\log (Y_{ik}) = \log (T_{ik}) + \sum_{j=1}^{k} \alpha_{j} x_{ij} + \sum_{l=1}^{l} \beta_{l} I(\tau_{l-1} < t_{ik} \leq \tau_{l}) + \sum_{a} \gamma_{a} z_{il}.
\]

\(Y_{ik}\) is the number of incident cases of prostate cancer, modelled to follow a Poisson distribution given the covariates, \(T_{ik}\) is the total person time at risk, each for a particular stratum \(i\) and time interval \(k\), and \(t_{ik}\) is the time since exposure. The exposures are indicated by the values of \(x_{ij}\), a binary variable taking the value of 1 for the WTC-exposed cohort, and 0 for the comparison NYS general population, and \(z_{il}\) represent demographic covariates age, and race/ethnicity. The \(\beta_{l}\)'s are dummy variables representing the 1-year time intervals. \(\beta_{l}\) is the log HR, also having log-relative-rate interpretation, comparing incidence in the WTC-exposed cohort to the NYS reference population for time interval \(l\), which is the period between change points \(l-1\) and \(l\). The \(\alpha_{j}\) were parameters representing the baseline hazard as a function of time which has cases per person time interpretation. The equation is described in greater detail, elsewhere. This primary external analysis using NYS as a comparison controlled for race/ethnicity, age and calendar year.

Three secondary analyses were conducted. The first was an external analysis and also used NYS as the comparison population but employed time of arrival at the WTC site as the exposure variable. This analysis excluded participants who did not report either a specific period of time they were present at the WTC site or exposure to the dust cloud (n=3279).
Additionally, non-Hispanic American Indian (n=146) participants were removed because of low power. Person-time for the 18–19, 20–24 and 25–29 age strata were excluded due to small numbers (n=8 participants, 1 prostate cancer) which led to unstable parameter estimates. The final restricted population included 50961 participants for this secondary external analysis (figure 1B).

The second was an internal analysis that used the same exclusionary criteria but evaluated those who arrived at the WTC site between 13 September 2001 and 30 June 2002 as the referent category. This model controlled for smoking status at baseline (ever vs never) as well as the additional covariates used in the primary analysis. The same model equation applied to this internal analysis as to the primary analysis, except that there were three exposure categories (first arrival at WTC site on 11 September or caught in dust cloud; first arrived on 12 September; first arrived on 13 September 2001–30 June 2002). We also calculated adjusted baseline incidence rates stratified by exposure category. These graphs were created by including an interaction term between the exposure variable and calendar year, such that each group could vary with time. For this analysis, we applied a locally-weighted polynomial regression (LOESS) smoothing function for point estimates and associated 95% CI.

Third, we conducted several sensitivity analyses to address the potential for surveillance bias by restricting to late-stage prostate cancers (regional and distant tumours), only. That is, regional and distant tumours are defined as cancers that have metastasised from beyond the primary tumour (i.e., prostate) to neighbouring and distant lymph nodes or organs, respectively. Categorisations were made using SEER Summary Staging Manual 2000 coding instructions. For each analysis, change points were evaluated, separately.

Analyses were conducted using SAS V9.4 (SAS Institute) and R V3.6.0.29. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines and was approved by IRB at Albert Einstein College of Medicine, New York City Department of Health and Mental Hygiene, the New York State Department of Health, and all thirteen cancer registries. The Icahn School of Medicine at Mount Sinai IRB ruled the research exempt. Data that support the findings of the study may be obtained from the corresponding author (CBH) on reasonable request after approval by the Steering Committee for ‘Incidence, Latency and Survival of Cancer Following World Trade Center Exposure’ (NIOSH Cooperative Agreement U01 OH011932) in accordance with the study’s official data sharing plan.

RESULTS

The 54394 participants in the final analytic cohort yielded 1120 prostate cancer cases in 1120 participants diagnosed between 12 March 2002 and 31 December 2015, with 573512 person-years of follow-up. During the same period, and using the same inclusion criteria, 207252 cases were diagnosed in the NYS comparison population, with 10541392 person-years of follow-up. Demographic characteristics for the analytic cohort are presented in table 1. The mean age at diagnosis among prostate cancer cases was 60.3 (SD=7.9) and ranged from 35 to 93 years old. Compared with WTC responders without prostate cancer, WTC responders with prostate cancer were significantly more likely to be non-Hispanic White (75.1% vs 71.7%; p<0.001) or non-Hispanic Black (17.4% vs 8.3%; p<0.001) and were significantly less likely to be Hispanic (7.0% vs 14.8%; p<0.001). There were significantly more ever smokers among...
prostate cancer cases when compared with persons without prostate cancer (46.9% vs 38.9%; p<0.001). Among persons with and without prostate cancer, 92 (8.2% of 1,120) and 2,166 (4.1% of 53,274) had another (non-prostate) malignancy within the study period, respectively. Among persons with prostate cancer, the median (IQR) time from 11 September to diagnosis was 9.4 years (7.3, 12.1). The majority of cases were diagnosed between 2009–2015 (n=734; 66%).

Figure 2 displays adjusted incidence rates for the study. Models were centred on non-Hispanic white participants age 50–54 for both graphs and additionally, never smokers in the secondary models. **Figure 2A** illustrates an increased adjusted incidence among the WTC combined rescue/recovery cohort coinciding with a decreased incidence among the NYS comparison rates beginning in 2006. From 2009–2015, prostate cancer incidence decreased for both groups. Similarly, **figure 2A** illustrates an increased incidence beginning in 2006 for all exposure categories, followed by a gradual decline from 2009 to 2015. A dose–response trend was observed; however, rates were not significantly different for most calendar years, individually. We estimated change points in 2006 for the primary external analysis (95% CI: 2006 to 2008) (**figure 3A**), as well as the secondary external (95% CI: 2006 to 2008) (**figure 3B**), and internal analyses (95% CI: 2006 to 2007) (**figure 3C**). The majority of cases had localised (n=867; 77%) tumours, 15.3% were regional (n=171) and 2.5% were distant (n=28). Our sensitivity analysis restricting to only regional and distant tumours yielded no significant change points. However, when evaluating HRs over the entire study period (2002–2015), rates were significantly elevated (**figure 3D**).

**DISCUSSION**

In the current study, we observed an increased incidence of prostate cancer beginning 5.25 years postexposure among participants in the WTC combined rescue/recovery cohort. Starting in 2007 and continuing through the end of the study period in 2015, we found a 24% increased risk of prostate cancer relative to NYS rates. In internal analyses, a dose–response trend was observed in both the early (2002–2006) and later (2007–2015) periods of follow-up, with the largest risk estimated in the early period. The increased hazard among those who responded to the disaster earliest or were caught in the dust cloud suggests that a high intensity of exposure may have played some role in premature oncogenesis. Relative to NYS, however, a lower relative risk was observed in the initial period, particularly among those responders who arrived at the WTC disaster site latest.

Earlier assessments among participants followed at the FDNY, GRC, and WTCRC have all independently established an elevated risk for prostate cancer. Our findings were in agreement with these earlier findings, with the exception of the study conducted at the FDNY, which did not observe an increased risk for prostate cancer.

**Table 1**

<table>
<thead>
<tr>
<th>Year of diagnosis</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>119 (10.6)</td>
</tr>
<tr>
<td>2015</td>
<td>115 (10.3)</td>
</tr>
</tbody>
</table>

**Stage**

- Localised: 867 (77.4)
- Regional: 171 (15.3)
- Distant: 28 (2.5)
- Unknown: 54 (4.8)

**Other descriptive statistics**

- Mean (SD)
  - Age at diagnosis (years): 60.3 (7.9)
  - Age at end of follow-up (years): 65.1 (7.8)
  - Length of follow-up (years): 11.2 (2.5)

---

*a, Rescue/recovery workers that did not have a prostate cancer diagnosis in the study period; WTC, World Trade Center.*

---

**Figure 2**

Adjusted prostate cancer incidence rates. (a) WTC combined rescue recovery cohort versus NYS. WTC, NYS, comparison population; models are controlled for race/ethnicity and age; rates are centred at non-Hispanic white race/ethnicity and ages 50–54; rates are displayed per 100,000 person-years; blue lines: smoothed adjusting incidence curves for WTC combined rescue/recovery cohort; red lines: smoothed adjusting incidence curves for NYS comparison population. Line shadows represent 95% CI. (b) WTC combined rescue recovery cohort by exposure category models are controlled for race/ethnicity and age; rates are centred at non-Hispanic white race/ethnicity and ages 50–54; rates are displayed per 100,000 person-years; red lines: smoothed adjusting incidence curves for point estimates for each year of WTC combined rescue/recovery cohort who first arrived at the WTC disaster site on 11 September or were caught in the dust cloud; blue lines: smoothed adjusting incidence curves for WTC combined rescue/recovery cohort who first arrived at the WTC disaster site on 12 September; green lines: smoothed adjusting incidence curves for WTC combined rescue/recovery cohort who first arrived at the WTC disaster site on 13 September – 30 June 2002. Line shadows represent 95% CIs. There were 515/24,478 (2.1%), 188/9692 (1.9%) and 349/16,791 (2.1%) cases among participants in the 11 September or dust cloud, 12 September and 13 September or later exposure categories, respectively. NYS, New York State; WTC, World Trade Centre.
support of the previous studies, despite removing duplicate cases between the cohorts that could have artificially inflated risk estimates. This study combined the three cohorts, providing statistical power and identifying the specific period (2007–2015) when the risk appears to be greatest. We found the period from exposure to onset of cancer to be just over 5 years, shorter than prior non-WTC studies,1 35 which may reflect the carcinogenicity of exposures experienced at the main WTC disaster site. The finding of an internal positive, monotonic dose–response association during the early (2002–2006) and late (2007–2015) periods is noteworthy. This is especially relevant because certain occupational groups may be at additional risk of prostate cancer, irrespective of WTC exposure. In addition, after controlling for cigarette smoking, an important confounder and one of the few known behavioural risk factors linked to prostate cancer, the association was upheld for those who arrived at the disaster site earliest or were caught in the dust cloud. The results of our sensitivity analysis evaluating WTC-exposure and regional/distant tumours, argue against surveillance bias. We continued to observe a dose-response association despite the absence of a change point. This observation, in conjunction with our previous report of favourable survival outcomes among WTCHP participants, supports further use of this cohort for studying prostate cancer treatments and interventions.

Higher than general population rates of PSA screening among WTC-exposed responders may have played a role in the increase in prostate cancer incidence. It is noteworthy that although PSA testing is not a formal part of WTC medical monitoring examination, it is offered to older participants at FDNY exams. Moreover, disaster-related services including diagnostic evaluations for WTC-related cancers and treatment were added to the FDNY responders’ routine screening after 11 September, while other responders may be tested in other primary healthcare settings that offered comparable medical evaluation and treatment. Arguing against surveillance bias are prior studies which have demonstrated similar findings in WTC-exposed cohorts without known formal PSA testing.8 36 The findings of this combined cohort study are consistent with a study from the WTC-exposed GRC, which found: (1) an internal dose-response association using a well-defined exposure metric; (2) high rates of advanced stage tumours which argue against lead-time bias and (3) an association among young and old participants but no association among participants aged 55–69, a group which is historically screened most frequently.8 However, because we are unable to assess association between exposure and number of PSA monitoring visits, screening cannot be completely discounted for the observed effect.

This current study has several strengths. It is the first to analyse the time from exposure to onset of cancer, in detail, among WTC-exposed responders. In addition to our efforts to reduce the impacts of surveillance bias, another strength of this work is the rigorous efforts to address self-selection bias by removing cancers that occurred within 6 months of enrolment in a WTC cohort and by requiring enrolment prior to the initiation of cancer coverage in 2012.26 We also believe that this work will be of interest in the broader of context of disaster management, particularly when analysing time to cancer diagnosis among responders who attended signal events with similar exposures such as the Deepwater Horizon Oil explosion. This study used parametric survival modelling with change points to model the HR as a nonlinear function of time, similar to those used in non-WTC cancer research24 and in WTC-related respiratory research.23 In general, the amount of time for prostate cancer to develop in relation to carcinogens known to be present is understudied and thus, this work may begin to fill an important gap in the scientific literature. The use of relative rates rather than standardised incidence ratios avoids reliance on assumptions of proportional incidence across strata that may not be met. This method is also not unduly influenced by small strata.

Finally, a major strength of this study is the continued follow-up of three cohorts of WTC rescue/recovery workers, which has provided a unique opportunity to better understand time from exposure to cancer diagnoses in a human population after a time-delimited exposure to a broad spectrum of environmental carcinogens. The WTC combined rescue/recovery cohort allows for analytic flexibility by augmenting the statistical power
needed for studying cancer in longitudinal survival analyses. Researchers from the cohorts following these workers had previously agreed on a common exposure definition and identical case ascertainment using thirteen state cancer registries. The NYS Cancer Registry served as an “honest broker” by consolidating data from the three surveillance groups to ensure data security and confidentiality, harmonising data formats and deduplicating data from rescue/recovery workers followed by multiple cohorts so that they were counted once for analyses. Unfortunately, we did not have access to information about years of employment or potentially important occupational exposures. Another limitation is the absence of PSA testing data on the WTC combined rescue/recovery cohort among those who were tested, although a study on GRC responders failed to find a significant association between frequency of screening exams and prostate cancer incidence. Additional studies were unable to explore alternate biological pathways for prostate tumorigenesis such as those mediated by stress, we believe that it is beyond the scope of this study but warrants further exploration in the future. Finally, the WTC combined rescue/recovery cohort was likely a healthy subset of the general population prior to exposure and resided mostly in the greater New York region, which limits generalisability of these findings to less healthy participants in other regions of the country.

In summary, we observed an increased incidence of prostate cancer beginning 5.25 years postexposure, substantially shorter than findings from non-WTC studies. A dose–response trend was observed in both the early (2002–2006) and later (2007–2015) periods of follow-up. Evidence suggests a relationship between WTC exposure and prostate cancer not fully explained by random or systematic error. This research may increase understanding of the period between environmental exposure and cancer incidence in human populations. It increases the under-standing of long-term consequences of WTC exposure, informs surveillance efforts for future environmental disasters and may stimulate further research into environmental risk factors for cancer in this and other cohorts. Our findings support the need for continued research evaluating the burden of prostate cancer in WTC responders.

Author affiliations
1Department of Medicine, Division of Pulmonary Medicine, Montefiore Medical Center, Bronx, New York, USA
2Bureau of Health, New York City, World Trade Center Health Program, Fire Department of the City of New York, Brooklyn, New York, USA
3Department of Epidemiology and Population Health, Division of Epidemiology, Albert Einstein College of Medicine, Bronx, New York, USA
4Department of Genetics and Bioinformatics, Norwegian Institute of Public Health, Oslo, Norway
5Center for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway
6World Trade Center Health Registry, New York City Department of Health and Mental Hygiene, New York, New York, USA
7Bureau of Cancer Epidemiology, New York State Department of Health, Albany, New York, USA
8Department of Epidemiology and Population Health, Division of Epidemiology, Montefiore Medical Center, Bronx, New York, USA
9Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA
10Stony Brook Cancer Center, Stony Brook University, Stony Brook, New York, USA
11Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, Italy
12Department of Epidemiology & Population Health, Division of Biostatistics, Albert Einstein College of Medicine, Bronx, New York, USA

Twitter Charles B Hall @CharlesBHallPhD

Acknowledgements
We thank the 13 state cancer registries for carrying out record linkages: Bureau of Cancer Epidemiology, New York State Department of Health (DOH); Arizona Cancer Registry Department of Health Services (DOHS); California Cancer Registry, Department of Public Health (DPH); Connecticut Tumor Registry, Connecticut DPH; Florida Cancer Registry, Florida DOH; Massachusetts Cancer Registry, Massachusetts DPH; New Jersey State Cancer Registry, New Jersey DOH and Rutgers Cancer Institute of New Jersey; North Carolina Central Cancer Registry, State Center for Health Statistics; Ohio Cancer Incidence Surveillance System, Ohio DOH; Bureau of Health Statistics and Research, Pennsylvania DOH; Texas Cancer Registry, Texas Department of State Health Services, Virginia Cancer Registry, Virginia DOH, and Washington State Cancer Registry, Washington DOH.

Additional Acknowledgements and Disclaimers from individual State Cancer Registries: The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under cooperative agreement 5NU58DP006344; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201800321 awarded to the University of California, San Francisco, contract HHSN261201800330 awarded to the University of Southern California, and contract HHSN261201800009 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Institutes of Health, the Centers for Disease Control and Prevention or their Contractors and Subcontractors. The Connecticut Department of Public Health Human Resources and the Connecticut Department of Public Health approved this research project, which used data obtained from the Connecticut Department of Public Health. The Connecticut Department of Public Health does not endorse or assume any responsibility for any analyses, interpretations or conclusions based on the data. The authors assume full responsibility for all such analyses, interpretations and conclusions. The Florida cancer incidence data used in this report were collected by the Florida Cancer Data System (FCDS), the statewide cancer registry funded by the Florida Department of Health (DOH) and the Centers for Disease Control and Prevention National Program of Cancer Registries (CDC-NPCR). The views expressed herein are solely those of the author(s) and not necessarily reflect those of the DOH or CDC-NPCR. Cancer incidence data used in these analyses were obtained from the Ohio Cancer Incidence Surveillance System (OCISS), Ohio Department of Health (ODH), a cancer registry partially supported by the National Program of Cancer Registries at the Centers for Disease Control and Prevention (CDC) through Cooperative Agreement Number NU58DPD006284. Use of these data does not imply that ODH or CDC agrees or disagrees with the analyses, interpretations or conclusions in this report (or publication/presentation). These data were supplied by the Bureau of Health Statistics & Registries, Pennsylvania Department of Health, Harrisburg, Pennsylvania. The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations or conclusions.

Contributors
The manuscript was conceptualised by: DG, RZ-Q, DK, CBH and PB. The acquisition, analysis or interpretation of data for the work was done by: DG, RZ-Q, DK, JL, RMB, MRF, JEC, CBH and PB. All authors had a role in drafting this work or revising it critically for important intellectual content. All authors have read and agreed for this version to be published.

Funding
This research was supported through the National Institute for Occupational Safety and Health (NIOSH) cooperative agreements (U10OH101135, U10 OH101932, U01 OH101681, U01 OH101931, U01 OH101480) and contracts (200-2011-39317B, 200-2017-93325 and 200-2017-93326). This publication was supported by Cooperative Agreement Number US50000739 from the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), contract U50/000009 from the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), contract U50/ATU272750 from the Agency for Toxic Substances and Disease Registry (ATSDR), CDC, which included support from the National Center for Environmental Health, CDC, and by the New York City Department of Health and Mental Hygiene (NYC DOHMH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIOSH, CDC or the Department of Health and Human Services. This research was also supported by grant P30 CA013330 from the National Cancer Institute (NCI), NIH, National Cancer Institute (US5 DP006309).

Competing interests
None declared.

Patient consent for publication
Not required.

Ethics approval
All respondents who were members of any of the three cohorts and either provided informed consent for research or were covered under a research ethics board, or Institutional Review Board (IRB)-approved waiver of consent were eligible for inclusion in analyses. These include: the Albert Einstein College of Medicine/Montefiore Medical Center: IRB#2016-6692; the NYC Department of

© 2021 BMJ Publishing Group Ltd


© 2021 BMJ Publishing Group Ltd

Workplace

Occup Environ Med: first published as 10.1136/oemed-2021-107405 on 10 September 2021. Downloaded from http://oem.bmj.com/ on September 14, 2021 by guest. Protected by copyright.
Health and Mental Hygiene: IRB #16-130; the NY State Department of Health: IRB #16-052; and the Icahn School of Medicine at Mt. Sinai: IRB#: 16-00814.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available on reasonable request. Data that support the findings of the study may be obtained from the corresponding author (CBH) upon reasonable request after approval by the Steering Committee for ‘Incidence, Latency and Survival of Cancer Following World Trade Center Exposure’ (NIOSH Cooperative Agreement U01 OH01932) in accordance with the study’s official Data Sharing Plan.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID IDs
David G Goldfarb http://orcid.org/0000-0003-2682-7543
Rachel Zeig-Owens http://orcid.org/0000-0002-8679-2306
Dana Kristjansson http://orcid.org/0000-0003-0687-2910
Jiehui Li http://orcid.org/0000-0002-7812-8878
Robert Mark Brackbill http://orcid.org/0000-0003-0518-0330
Mark R Farfel http://orcid.org/0000-0002-9952-9937
James E Cone http://orcid.org/0000-0003-2145-1348
Janette Yung http://orcid.org/0000-0002-9463-2092
Amy R Kahn http://orcid.org/0000-0002-1025-6312
Baozhen Qiao http://orcid.org/0000-0002-8407-7835
Mayris P Webber http://orcid.org/0000-0002-8322-4573
Christopher R Dasaro http://orcid.org/0000-0002-9924-195X
Moshe Shapiro http://orcid.org/0000-0002-9081-9743
Andrew C Todd http://orcid.org/0000-0001-7864-009X
David J Prezant http://orcid.org/0000-0001-9562-0330
Paolo Boffetta http://orcid.org/0000-0002-3811-2791
Charles B Hall http://orcid.org/0000-0001-9982-8120

REFERENCES
17 Office N. When new Yorkers move out of new York City where do they go? 2014.